IL278295A - - Google Patents
Info
- Publication number
- IL278295A IL278295A IL27829520A IL27829520A IL278295A IL 278295 A IL278295 A IL 278295A IL 27829520 A IL27829520 A IL 27829520A IL 27829520 A IL27829520 A IL 27829520A IL 278295 A IL278295 A IL 278295A
- Authority
- IL
- Israel
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261737035P | 2012-12-13 | 2012-12-13 | |
| PCT/US2013/073825 WO2014093203A1 (en) | 2012-12-13 | 2013-12-09 | SOLUTION FORMULATIONS OF ENGINEERED ANTI-IL-23p19 ANTIBODIES |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL278295A true IL278295A (OSRAM) | 2020-12-31 |
| IL278295B1 IL278295B1 (en) | 2023-11-01 |
| IL278295B2 IL278295B2 (en) | 2024-03-01 |
Family
ID=50934859
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL278295A IL278295B2 (en) | 2012-12-13 | 2013-12-09 | SOLUTION FORMULATIONS OF ENGINEERED ANTI-IL-23p19 ANTIBODIES |
| IL307581A IL307581A (en) | 2012-12-13 | 2013-12-09 | Information on a solution of engineered anti–IL23–P19 antibodies |
| IL239150A IL239150B (en) | 2012-12-13 | 2015-06-02 | Solution formulations of engineered anti–p19–il23 antibodies |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL307581A IL307581A (en) | 2012-12-13 | 2013-12-09 | Information on a solution of engineered anti–IL23–P19 antibodies |
| IL239150A IL239150B (en) | 2012-12-13 | 2015-06-02 | Solution formulations of engineered anti–p19–il23 antibodies |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US20210188964A1 (OSRAM) |
| EP (1) | EP2931313B1 (OSRAM) |
| JP (1) | JP6266012B2 (OSRAM) |
| KR (1) | KR102004585B1 (OSRAM) |
| CN (1) | CN104870016B (OSRAM) |
| AU (1) | AU2013359767B2 (OSRAM) |
| BR (1) | BR112015013540B1 (OSRAM) |
| CA (1) | CA2894869C (OSRAM) |
| CL (1) | CL2015001608A1 (OSRAM) |
| CY (1) | CY1121895T1 (OSRAM) |
| DK (1) | DK2931313T3 (OSRAM) |
| EA (1) | EA034616B1 (OSRAM) |
| ES (1) | ES2732861T3 (OSRAM) |
| HR (1) | HRP20191137T1 (OSRAM) |
| HU (1) | HUE045668T2 (OSRAM) |
| IL (3) | IL278295B2 (OSRAM) |
| LT (1) | LT2931313T (OSRAM) |
| MX (1) | MX357936B (OSRAM) |
| MY (1) | MY187921A (OSRAM) |
| NZ (1) | NZ708443A (OSRAM) |
| PE (1) | PE20151524A1 (OSRAM) |
| PH (1) | PH12015501296B1 (OSRAM) |
| PL (1) | PL2931313T3 (OSRAM) |
| PT (1) | PT2931313T (OSRAM) |
| RS (1) | RS59057B1 (OSRAM) |
| SI (1) | SI2931313T1 (OSRAM) |
| SM (1) | SMT201900414T1 (OSRAM) |
| TR (1) | TR201909584T4 (OSRAM) |
| UA (1) | UA117466C2 (OSRAM) |
| WO (1) | WO2014093203A1 (OSRAM) |
| ZA (1) | ZA201504408B (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI738632B (zh) | 2014-11-07 | 2021-09-11 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
| JP7179717B2 (ja) * | 2017-03-31 | 2022-11-29 | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | 水性製剤及び注射器入り水性製剤、並びに、抗体タンパク脱凝集剤及び抗体タンパク脱凝集方法 |
| US20190269757A1 (en) * | 2018-03-05 | 2019-09-05 | Janssen Biotech, Inc. | Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody |
| US12036280B2 (en) * | 2018-11-21 | 2024-07-16 | Regeneron Pharmaceuticals, Inc. | High concentration protein formulation |
| JP7517999B2 (ja) | 2018-11-27 | 2024-07-17 | イノベント バイオロジックス （スウツォウ） カンパニー，リミテッド | 抗ＩＬ－２３ｐ１９抗体およびその使用 |
| JP7530376B2 (ja) * | 2019-02-20 | 2024-08-07 | アムジエン・インコーポレーテツド | タンパク質の安定性を決定する方法 |
| KR20220012883A (ko) | 2019-05-23 | 2022-02-04 | 얀센 바이오테크 인코포레이티드 | Il-23 및 tnf 알파에 대한 항체의 병용요법으로 염증성 장질환을 치료하는 방법 |
| TW202123965A (zh) * | 2019-09-09 | 2021-07-01 | 德商百靈佳殷格翰國際股份有限公司 | 抗-il-23p19抗體調配物 |
| CA3164996A1 (en) | 2019-12-20 | 2021-06-14 | Novarock Biotherapeutics, Ltd. | Anti-interleukin-23 p19 antibodies and methods of use thereof |
| BR112022022919A2 (pt) * | 2020-05-13 | 2022-12-20 | Innovent Biologics Suzhou Co Ltd | Formulação compreendendo o anticorpo anti-il-23p19, método para preparar o mesmo e uso do mesmo". |
| BR112022023489A2 (pt) | 2020-05-21 | 2023-03-14 | Janssen Biotech Inc | Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa |
| WO2025071362A1 (ko) * | 2023-09-27 | 2025-04-03 | 삼성바이오에피스 주식회사 | 항-il-23 항체의 안정한 액상 제형 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000053631A1 (en) | 1999-03-11 | 2000-09-14 | Schering Corporation | Mammalian cytokines; related reagents and methods |
| IL148300A0 (en) | 1999-09-09 | 2002-09-12 | Schering Corp | Mammalian cytokines; related reagents and methods |
| CA2454587C (en) | 2001-07-25 | 2012-11-13 | Protein Design Labs, Inc. | Stable lyophilized pharmaceutical formulation of igg antibodies |
| IL161677A0 (en) * | 2001-11-08 | 2004-09-27 | Protein Design Labs | Stable liquid pharmaceutical formulation of igg antibodies |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| WO2004071517A2 (en) | 2003-02-06 | 2004-08-26 | Schering Corporation | Uses of il-23 related reagents |
| RU2358763C2 (ru) | 2003-02-10 | 2009-06-20 | Элан Фармасьютикалз, Инк. | Композиции иммуноглобулина и способ их получения |
| JP4605798B2 (ja) | 2003-03-10 | 2011-01-05 | シェーリング コーポレイション | Ｉｌ−２３アゴニストおよびｉｌ−２３アンタゴニスト；関連試薬の使用 |
| DK2335725T3 (en) * | 2003-04-04 | 2017-01-23 | Genentech Inc | Highly concentrated antibody and protein formulations |
| CN1942201B (zh) | 2004-02-17 | 2012-06-20 | 先灵公司 | 调节il-23活性的方法；相关试剂 |
| AU2005249360B2 (en) | 2004-04-12 | 2011-07-21 | Medimmune, Llc | Anti-IL-9 antibody formulations and uses thereof |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| GT200600031A (es) | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
| ES2410406T3 (es) | 2005-06-30 | 2013-07-01 | Janssen Biotech, Inc. | Anticuerpos anti-IL-23, composiciones, procedimientos y usos |
| EP1937721B1 (en) | 2005-08-25 | 2010-07-28 | Eli Lilly And Company | Anti-il-23 antibodies |
| HUE032131T2 (en) | 2005-08-31 | 2017-09-28 | Merck Sharp & Dohme | Constructed anti-IL-23 antibodies |
| EP3219328B1 (en) | 2005-12-29 | 2020-06-17 | Janssen Biotech, Inc. | Human anti-il-23 antibodies, compositions, method and uses |
| AU2007260787A1 (en) | 2006-06-13 | 2007-12-21 | Zymogenetics, Inc | IL-17 and IL-23 antagonists and methods of using the same |
| WO2008051363A2 (en) | 2006-10-20 | 2008-05-02 | Amgen Inc. | Stable polypeptide formulations |
| CL2008000058A1 (es) | 2007-01-09 | 2008-05-23 | Wyeth Corp | Formulacion que comprende un anticuerpo anti-il13, un criprotector, y una solucion amortiguadora; composicion farmaceutica que la comprende; metodo para tratar un trastorno relacionado con il13; y formas farmaceuticas que la comprenden. |
| TWI426918B (zh) | 2007-02-12 | 2014-02-21 | Merck Sharp & Dohme | Ｉｌ-２３拮抗劑於治療感染之用途 |
| EP2064242A1 (en) | 2007-02-23 | 2009-06-03 | Schering Corporation | Engineered anti-il-23p19 antibodies |
| ATE554791T1 (de) * | 2007-02-23 | 2012-05-15 | Schering Corp | Gentechnisch hergestellte anti-il-23p19- antikörper |
| WO2008121615A2 (en) * | 2007-03-30 | 2008-10-09 | Medimmune, Inc. | Antibody formulation |
| US20090208492A1 (en) * | 2007-06-14 | 2009-08-20 | Elan Pharmaceuticals, Inc. | Lyophilized Immunoglobulin Formulations and Methods of Preparation |
| EP2205276A4 (en) | 2007-09-28 | 2012-08-15 | Janssen Biotech Inc | ANTI-IL-12 / 23P40 ANTIBODIES, EPITOPES, FORMULATIONS, COMPOSITIONS, METHODS AND USES |
| AR068723A1 (es) | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
| NZ585516A (en) | 2007-12-21 | 2012-07-27 | Hoffmann La Roche | Anti-cd20 antibody formulation |
| NZ589434A (en) * | 2008-06-03 | 2012-11-30 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| WO2010027766A1 (en) * | 2008-08-27 | 2010-03-11 | Schering Corporation | Lyophilized formulatons of engineered anti-il-23p19 antibodies |
| TR201802935T4 (tr) * | 2008-09-19 | 2018-03-21 | Pfizer | Stabil sıvı antikor formülasyonu. |
| JP2012510468A (ja) * | 2008-11-28 | 2012-05-10 | アボット・ラボラトリーズ | 安定な抗体組成物およびこれを安定させるための方法 |
| EP2519262A2 (en) * | 2009-12-29 | 2012-11-07 | F. Hoffmann-La Roche AG | Antibody formulation |
| KR102031020B1 (ko) | 2011-03-31 | 2019-10-14 | 머크 샤프 앤드 돔 코포레이션 | 인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료 |
-
2013
- 2013-09-12 UA UAA201506824A patent/UA117466C2/uk unknown
- 2013-12-09 WO PCT/US2013/073825 patent/WO2014093203A1/en not_active Ceased
- 2013-12-09 KR KR1020157018314A patent/KR102004585B1/ko active Active
- 2013-12-09 PT PT13863590T patent/PT2931313T/pt unknown
- 2013-12-09 JP JP2015547448A patent/JP6266012B2/ja active Active
- 2013-12-09 PE PE2015000925A patent/PE20151524A1/es active IP Right Grant
- 2013-12-09 ES ES13863590T patent/ES2732861T3/es active Active
- 2013-12-09 EP EP13863590.9A patent/EP2931313B1/en active Active
- 2013-12-09 BR BR112015013540-4A patent/BR112015013540B1/pt active IP Right Grant
- 2013-12-09 HU HUE13863590A patent/HUE045668T2/hu unknown
- 2013-12-09 TR TR2019/09584T patent/TR201909584T4/tr unknown
- 2013-12-09 IL IL278295A patent/IL278295B2/en unknown
- 2013-12-09 SI SI201331504T patent/SI2931313T1/sl unknown
- 2013-12-09 AU AU2013359767A patent/AU2013359767B2/en active Active
- 2013-12-09 NZ NZ708443A patent/NZ708443A/en unknown
- 2013-12-09 IL IL307581A patent/IL307581A/en unknown
- 2013-12-09 PL PL13863590T patent/PL2931313T3/pl unknown
- 2013-12-09 HR HRP20191137TT patent/HRP20191137T1/hr unknown
- 2013-12-09 DK DK13863590.9T patent/DK2931313T3/da active
- 2013-12-09 EA EA201591133A patent/EA034616B1/ru unknown
- 2013-12-09 MY MYPI2015701965A patent/MY187921A/en unknown
- 2013-12-09 LT LTEP13863590.9T patent/LT2931313T/lt unknown
- 2013-12-09 RS RS20190822A patent/RS59057B1/sr unknown
- 2013-12-09 CA CA2894869A patent/CA2894869C/en active Active
- 2013-12-09 MX MX2015007213A patent/MX357936B/es active IP Right Grant
- 2013-12-09 CN CN201380065606.7A patent/CN104870016B/zh active Active
- 2013-12-09 SM SM20190414T patent/SMT201900414T1/it unknown
-
2015
- 2015-06-02 IL IL239150A patent/IL239150B/en active IP Right Grant
- 2015-06-08 PH PH12015501296A patent/PH12015501296B1/en unknown
- 2015-06-10 CL CL2015001608A patent/CL2015001608A1/es unknown
- 2015-06-18 ZA ZA2015/04408A patent/ZA201504408B/en unknown
-
2019
- 2019-06-27 CY CY20191100675T patent/CY1121895T1/el unknown
-
2020
- 2020-12-08 US US17/114,754 patent/US20210188964A1/en active Pending
-
2024
- 2024-01-05 US US18/405,772 patent/US20240239884A1/en active Pending